cas 22715-27-1|| where to buy 2,5-Diaminepyrimidine

Produktname:2,5-Diaminepyrimidine

IUPAC Name:pyrimidine-2,5-diamine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM167296-250mg	in stock	ŵǜ
CM167296-1g	in stock	ƛȐƿ
CM167296-5g	in stock	ŵȡƥ
CM167296-25g	in stock	ƛǜǶȐ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 22715-27-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:22715-27-1; Molekulare Formel:C4H6N4; Schmelzpunkt:-; SMILES-Code:C1=C(N)C=NC(=N1)N; Dichte:

: Katalognummer:CM167296; Molekulargewicht:110.12; Siedepunkt:; Mdl-Nr.:MFCD00129726; Lagerung:Store at 2-8°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: STX-478; Scorpion presented initial, first-in-human clinical results from its Phase 1/2 study of STX-478 in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Initial Phase 1 monotherapy data for STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated potentially best-in-class PI3Kα inhibition, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors. STX-478 was well-tolerated, including in pre-diabetic, diabetic and heavily pre-treated patients and showed no significant wild-type-mediated toxicities.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.